InnoCare swings to profit of RMB 239.7 million in H1 FY26; revenue climbs 55.5% to RMB 1.1 billion

• InnoCare revenue rose 55.5% year-on-year to RMB 1.1 billion in the six months ended June 30, 2026.
• Profit swung to RMB 239.7 million from a loss a year earlier, on higher commercial growth and global business development collaborations.
• Drug sales climbed 43.2% to RMB 918.1 million, driven by orelabrutinib growth and new launches of tafasitamab and zurletrectinib.
• R&D investment increased 10.5% to RMB 497.1 million; cash and related accounts totaled about RMB 8.4 billion at June 30.
• Jasmine Cui said InnoCare sustained profitability, expanded commercialization, advanced Phase III programs, and will accelerate its Strategy 2.0 global push.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608241032PRIMZONEFULLFEED9814933) on August 24, 2026, and is solely responsible for the information contained therein.